News

AbstractInterpreting composite endpoints in cardiovascular drug development is a key challenge, particularly when events of different clinical relevance are…

Long-term treatment with diflunisal may help slow disease progression in people with hereditary transthyretin amyloidosis (hATTR), according to a Swedish real-world…

AbstractCardiac amyloidosis is a clinical condition characterized by deposition of amyloid fibrils in the myocardium, leading to increased left ventricular wall…

In transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM), high left ventricular (LV) amyloid load is associated with cardiac dysfunction, including worse global…

There are many well-known benefits of strength training, including stronger bones and muscles, improved heart health, and decreased abdominal fat.A new study…

AbstractBackground: Cardiac Amyloidosis (CA), specifically Transthyretin Amyloid Cardiomyopathy (ATTR-CM), is an under-recognized, progressive, and fatal disease.…

Many patients evaluated for two common forms of cardiac amyloidosis never received the testing recommended to confirm or rule out the diseases, a large analysis of…

AbstractIn a first-in-human trial (NI006-101), the monoclonal antibody cliramitug, targeting misfolded transthyretin, demonstrated a favorable safety profile and…

Brief SummaryThis study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a…

Trial Purpose and DescriptionThis is a Phase I/II, multi-center, open-label study designed to evaluate the safety, tolerability and efficacy of elranatamab in…